Abstract
Background :
Metformin, a biguanide primarily used for the treatment of type 2 diabetes mellitus, has attracted significant attention for its potential anti-aging effects. As aging becomes the primary risk factor for chronic diseases, interventions targeting fundamental aging processes are gaining traction in biomedical research.
Mechanisms of Action:
Accumulating evidence suggests that metformin exerts geroprotective effects through multiple interconnected pathways. These include activation of AMP-activated protein kinase (AMPK), inhibition of the mechanistic target of rapamycin (mTOR), attenuation of oxidative stress, modulation of mitochondrial biogenesis, and reduction of low-grade systemic inflammation. Together, these actions address key hallmarks of aging such as cellular senescence, dysregulated nutrient sensing, and altered proteostasis.
Preclinical and Clinical Evidence:
Animal studies have consistently shown that metformin extends both lifespan and healthspan. In humans, retrospective epidemiological data indicate reduced incidence of cancer, cardiovascular disease, and cognitive decline among metformin users. The TAME (Targeting Aging with Metformin) trial represents the first large-scale attempt to formally assess aging-related outcomes in a non-diabetic population.
Challenges and Perspectives:
Despite promising data, uncertainties remain regarding optimal dosing, long-term safety, and applicability in healthy aging populations. Furthermore, individual variability in response to metformin suggests the need for precision medicine approaches.
Conclusion:
Metformin stands at the intersection of metabolic regulation and aging biology. While not a panacea, its favorable safety profile and multi-targeted actions make it a leading candidate for repurposing as an anti-aging therapy. Continued clinical validation is essential to translate these insights into practice.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.